<DOC>
	<DOCNO>NCT01804374</DOCNO>
	<brief_summary>This trial patient affect metastatic relapsed osteosarcoma progress first line treatment . In trial , patient treat progression unacceptable toxicity sorafenib everolimus . The treatment sorafenib everolimus aim obtain 50 % rate patient free progression disease 6 month study entry .</brief_summary>
	<brief_title>Phase II Open Label , Non-randomized Study Sorafenib Everolimus Relapsed Non-resectable Osteosarcoma</brief_title>
	<detailed_description>Patients affect metastatic relapsed osteosarcoma progress first line treatment still poor outcome . Standard chemotherapy limited activity patient . In previous study patient affect relapsed unresectable osteosarcoma , sorafenib alone demonstrated promising activity . In preclinical setting , everolimus able improve activity sorafenib . Sorafenib everolimus , hit crucial pathway essential osteosarcoma cell proliferation survival , entirely different approach aim overcome resistance standard chemotherapy show relapsed osteosarcoma . In trial , patient treat sorafenib everolimus dosage 800 mg 5 mg per day , respectively . Both drug take orally . The treatment continue progression unacceptable toxicity . The objective present trial obtain 50 % rate patient alive free progression disease 6 month trial enrolment . The disease evaluate every 2 month CT scan .</detailed_description>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients histologically document surgically resectable metastatic highgrade osteosarcoma progress first second line treatment relapse disease Measurable disease define RECIST criterion vs. 1.1 ( bone lesion allow ) . Baseline evaluation must complete within 28 day prior enrollment Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 . ECOG PS 2 patient eligible PS 2 depend solely orthopedic problem Estimated life expectancy least 3months Age≥18 year Adequate bone marrow , liver renal function : Hemoglobin &gt; 9.0g/dl , Absolute neutrophil count &gt; 1,500/mm3 , Platelet &gt; 100,000/μl Total bilirubin &lt; 1.5 time upper limit normal ( ULN ) , ALT AST &lt; 2.5xULN ( &lt; 5xULN patient liver involvement cancer ) , PTINR/PTT &lt; 1.5xULN , Serum creatinine &lt; 2xULN Written inform consent Dementia significantly alter mental status would prohibit understanding rendering informed consent compliance requirement protocol Patients severe and/or uncontrolled medical condition unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction ≤6months , serious uncontrolled cardiac arrhythmia , uncontrolled hyperlipidemia , active uncontrolled severe infection , cirrhosis , chronic persistent active hepatitis severely impaired lung function . History HIV infection active clinically serious infection ( &gt; grade 2 accord NCICTCAE vs. 4.0 ) Symptomatic metastatic brain meningeal tumor ( unless patient &gt; 6months definitive therapy , negative imaging study within 4weeks study entry clinically stable respect tumor time study entry ) Patients seizure disorder require medication Pregnant breastfeeding patient . Women childbearing potential must negative pregnancy test perform within 7days start treatment . Both men woman must use adequate barrier birth control measure course trial 8weeks last dose study drug Patients evidence history bleed diathesis Patients undergoing renal dialysis Patients unable swallow oral medication Uncontrolled diabetes ( fast glucose &gt; 2xULN ) Patients receive chronic , systemic treatment corticosteroid another immunosuppressive agent ( except corticosteroid daily dosage equivalent prednisone ≤20mg adrenal insufficiency ) . Patients receive corticosteroid must stable dose ≥4weeks prior first dose Everolimus . Topical inhale corticosteroid permit Patients history another malignancy within 5years prior study entry , except curatively treat nonmelanotic skin cancer insitu cervical cancer skin solid tumor curatively treat evidence disease ≥3years . Patients severe and/or uncontrolled concurrent medical disease opinion investigator could cause unacceptable safety risk compromise compliance protocol Anticancer chemotherapy immunotherapy study within 4weeks study entry Radiotherapy study within 3weeks start study drug . ( Palliative radiotherapy allow ) Major surgery within 4weeks start study Investigational drug therapy outside trial within 4weeks study entry Prior exposure study drug analogues Patients know hypersensitivity sorafenib , everolimus rapamycin analog , excipients Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result A history noncompliance medical regimen inability unwillingness return schedule visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>osteosarcoma</keyword>
	<keyword>sorafenib</keyword>
	<keyword>everolimus</keyword>
	<keyword>sarcoma</keyword>
</DOC>